Procter & Gamble Health Share Price

Procter & Gamble Health Share Price

NSE: PGHL
|
Pharmaceuticals
|
S Cap
ā‚¹ 0.00
+0.00 (0.00%)
1D
--
--
--
1D LOW
1D HIGH

Procter & Gamble Health Returns Calculator

Circuit
L
H
--
--
52-week
L
H
--
--

About Procter & Gamble Health

Procter & Gamble Health Share Price
ISIN
INE199A01012
Sector Market Cap
ā‚¹ 9,032.14 Cr

Procter & Gamble Health Limited is an India-based multinational consumer goods company. The Company is focused on manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company is engaged in the manufacturing and selling of healthcare products, such as vitamins, minerals and supplements. Patients are end consumers of the products. The Companyā€™s distribution channels (direct and indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. The Companyā€™s brands include Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Seven Seas is a pure vitamin rich cod-liver oil. Neurobion offers a range of neurotropic supplements. Its products are sold in about 180 countries and territories throughout the world.

Procter & Gamble Health Financial Highlights

  • Revenue: Procter & Gamble Health reported revenue of ā‚¹1,425.31 crore in FY26 vs ā‚¹944.52 crore in FY25. It showed an increase of 50.90% on a yearly basis.
  • Operating Profit: Procter & Gamble Health reported an operating profit of ā‚¹449.86 crore in FY26 vs ā‚¹311.62 crore in FY25. It showed an increase of 44.36% on a year-on-year basis.
  • Net Profit: Procter & Gamble Health reported a net profit of ā‚¹326.91 crore in FY26 vs ā‚¹234.41 crore in FY25. It showed an increase of 39.46% on a yearly basis.

Procter & Gamble Health Quarterly Result Highlights

  • Procter & Gamble Health reported revenue of ā‚¹367.59 crore in Jun 2026, compared with ā‚¹374.45 crore in Mar 2026, representing a decrease of 1.83% on a quarter-on-quarter (QoQ) basis.
  • Procter & Gamble Health reported an operating profit of ā‚¹129.12 crore in Jun 2026, compared with ā‚¹133.21 crore in Mar 2026, representing a decrease of 3.07% on a quarter-on-quarter (QoQ) basis.
  • Procter & Gamble Health reported a profit of ā‚¹96.15 crore in Jun 2026, compared with ā‚¹94.60 crore in Mar 2026, reflecting an increase of 1.64% on a QoQ basis.
  • The earnings per share (EPS) of Procter & Gamble Health stood at ā‚¹141.00 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
51.82%
FII
6.33%
Other DII
3.39%
Retail and other
29.42%
Mutual funds
9.05%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20257.24%
Dec 20256.97%
Mar 20266.20%
Jun 20266.33%
Mkt Cap Cr
9,032.14
P/E
25.31
P/B
17.22
ROE
62.32%
D/E
0.02
ROCE
84.14%
Div. Yield
3.77%
EPS(TTM)
196.94
Turnover
1.70
EV/EBITDA
17.26
Net Margin
20.86%
Op. Margin
30.24%
ROA
42.42%
Quick Ratio
1.65
Curr. Ratio
2.21
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
P & G Health Ltd has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
P & G Health Ltd appears overvalued compared to its peers
Peer Comparison
Peer comparison ā€” key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,42,437.0036.935.3513.74%0.6117.33%93.240.87%0.4810.90
Divis Laboratories2,48,054.0087.1015.2015.32%0.0019.56%629.490.32%0.5598.19
Torrent Pharmaceuticals1,89,842.0087.8622.5325.49%1.6913.85%222.760.68%0.4958.70
Zydus Lifesciences1,15,810.0025.404.3018.59%0.3117.35%237.300.09%0.3335.38
Cipla1,11,565.0033.223.2411.27%0.0014.95%423.360.94%0.4543.52
Laurus Labs1,08,338.00100.8320.7416.77%0.4016.14%97.200.10%0.6713.72
Mankind Pharma1,01,712.0049.196.2411.74%0.3413.13%396.980.04%0.4449.37
Dr. Reddy's Laboratories1,01,163.0031.732.6511.07%0.1812.54%377.950.66%0.4138.68
Aurobindo Pharma97,641.6026.752.629.25%0.1911.76%394.820.24%0.3841.58
Lupin96,030.9017.304.2823.76%0.0424.88%658.960.86%0.57129.18

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Procter & Gamble Health Financials

Full statement

Income Statement Ā· Standalone

Income Statement Ā· Standalone ā€” all values in INR Crore
ParticularsMar 2025Jun 2024Jun 2023Jun 2022
Revenueā‚¹934.17ā‚¹1,151.26ā‚¹1,229.62ā‚¹1,114.41
Other Incomeā‚¹10.35ā‚¹15.63ā‚¹18.39ā‚¹13.19
Total Revenueā‚¹944.52ā‚¹1,166.89ā‚¹1,248.01ā‚¹1,127.60
Total Expensesā‚¹632.90ā‚¹873.38ā‚¹933.81ā‚¹874.23
Profit Before Taxā‚¹311.62ā‚¹273.32ā‚¹314.20ā‚¹253.37
Taxā‚¹77.21ā‚¹72.34ā‚¹84.73ā‚¹60.85
Profit After Taxā‚¹234.41ā‚¹200.98ā‚¹229.47ā‚¹192.52
EPS - Basicā‚¹141.00ā‚¹121.00ā‚¹138.00ā‚¹116.00
EPS - Dilutedā‚¹141.00ā‚¹121.00ā‚¹138.00ā‚¹116.00

Cash Flow Ā· Standalone

Cash Flow Ā· Standalone ā€” all values in INR Crore
ParticularsMar 2026Mar 2025Jun 2024Jun 2023
Profit before taxā‚¹449.86ā‚¹311.62ā‚¹273.32ā‚¹314.20
Income before WC changesā‚¹465.04ā‚¹323.82ā‚¹325.59ā‚¹355.69
Change in Assets-ā‚¹73.84-ā‚¹69.92ā‚¹70.57-ā‚¹97.15
Change in Liabilitiesā‚¹50.44-ā‚¹3.89-ā‚¹82.68ā‚¹67.13
Change in WC-ā‚¹23.40-ā‚¹73.81-ā‚¹12.11-ā‚¹30.02
Cash flow from Operationsā‚¹337.79ā‚¹168.69ā‚¹228.29ā‚¹236.01
Cash flow from Investingā‚¹1.26ā‚¹9.59-ā‚¹6.87-ā‚¹21.50
Cash flow from Financing-ā‚¹343.92-ā‚¹234.74-ā‚¹418.11-ā‚¹98.49
Total Cash Flow-ā‚¹4.87-ā‚¹56.46-ā‚¹196.69ā‚¹116.02
Cash (Start of the year)ā‚¹182.27ā‚¹238.73ā‚¹435.42ā‚¹319.40
Cash (End of the year)ā‚¹177.40ā‚¹182.27ā‚¹238.73ā‚¹435.42

Balance Sheet Ā· Standalone

Balance Sheet Ā· Standalone ā€” all values in INR Crore
ParticularsMar 2025Jun 2024Jun 2023Jun 2022
Non-Current Assetsā‚¹267.81ā‚¹270.14ā‚¹305.09ā‚¹280.08
Current Assetsā‚¹526.39ā‚¹524.22ā‚¹796.10ā‚¹608.04
Total Assetsā‚¹794.20ā‚¹794.36ā‚¹1,101.19ā‚¹888.12
Current Liabilitiesā‚¹215.31ā‚¹218.91ā‚¹303.90ā‚¹231.90
Net Current Assetā‚¹311.08ā‚¹305.31ā‚¹492.20ā‚¹376.14
Non-Current Liabilitiesā‚¹41.93ā‚¹37.21ā‚¹46.40ā‚¹39.73
Equity Capitalā‚¹536.96ā‚¹538.24ā‚¹750.89ā‚¹616.49
Total Equity & Liabilitiesā‚¹794.20ā‚¹794.36ā‚¹1,101.19ā‚¹888.12
* All values are in INR Crore
Qty
Bid
Ask
Qty
Bid Total: 0
Ask Total: 0
Buy orders: 0%
Sell orders: 0%
Bearish
2
Neutral
6
Bullish
0
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
33.16
Neutral
ATR (14)
117.82
Neutral
STOCH(9,6)
56.31
Neutral
STOCH RSI (14)
60.12
Neutral
ADX(9)
43.85
Bearish
UO(9)
41.14
Neutral
ROC(12)
-3.67
Bearish
WillR(14)
-68.69
Neutral
Period
Simple value
Exponential vaue
5D
5470.5
5466.96
10D
5453.25
5494.26
20D
5579.63
5593.5
50D
6026.88
5823.93
100D
6002.85
5841.18
Volume trend ā€” traded volume by day
23Ā Sep0L
22Ā Sep0L
21Ā Sep0L
18Ā Sep0L
17Ā Sep0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Procter & Gamble Health Share Price
Procter & Gamble Health
Pharmaceuticals
Add Stock
Add Another

Procter & Gamble Health Share Price FAQs

Procter & Gamble Health share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837